

The idiopathic hypereosinophilic syndrome.

Weller PF, Bubley GJ. *Blood*. 1994 May 15;83(10):2759-79.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. *J Allergy Clin Immunol*. 2009 Dec;124(6):1319-25.

French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Groh M, Rohmer J, Etienne N, Abou Chahla W, Baudet A, Chan Hew Wai A, Chenivresse C, Clisson Rusek I, Cottin V, Decamp M, De Groote P, Delahousse F, Duployez N, Faguer S, Gottrand F, Huang F, Leblanc T, Magnan A, Martin T, Mortuaire G, Néel A, Paris L, Petit A, Rossignol J, Schleinitz N, Soret-Dulphy J, Staumont-Salle D, Terrier B, Terriou L, Viallard JF, Lefèvre G, Kahn JE. *Orphanet J Rare Dis*. 2023 Apr 30;18(1):100. doi: 10.1186/s13023-023-02696-4.

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.

Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. *Allergy*. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544.

Myeloid neoplasms with eosinophilia. Reiter A, Gotlib J. *Blood*. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973.

#### EXTRAS:

Approach to the patient with suspected hypereosinophilic syndrome.

Klion AD. *Hematology Am Soc Hematol Educ Program*. 2022 Dec 9;2022(1):47-54. doi: 10.1182/hematology.2022000367.

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.

Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ; HES Mepolizumab study group. *J Allergy Clin Immunol*. 2020 Dec;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037.

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

Shomali W, Gotlib J. *Am J Hematol*. 2024 May;99(5):946-968. doi: 10.1002/ajh.27287.